Literature DB >> 15384017

Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Jürgen Bommer1, Francesco Locatelli, Sudtida Satayathum, Marcia L Keen, David A Goodkin, Akira Saito, Takashi Akiba, Friedrich K Port, Eric W Young.   

Abstract

BACKGROUND: Experimental and some clinical data suggest that metabolic acidosis contributes to poor nutritional status, a strong predictor for mortality in hemodialysis patients. However, recent cross-sectional studies indicate that severe predialysis metabolic acidosis is associated with a greater normalized protein catabolic rate (nPCR) and greater serum albumin levels. Given this controversy, we analyzed data from the Dialysis Outcomes and Practice Pattern Study (DOPPS) for associations between predialysis serum bicarbonate and albumin concentrations, nPCR, and patient risk for mortality and hospitalization.
METHODS: Data from more than 7,000 representative and randomly selected hemodialysis DOPPS patients from France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States were analyzed. Serum bicarbonate (total CO2 ) levels predialysis were corrected to the midweek interdialytic interval.
RESULTS: The midweek predialysis serum bicarbonate level averaged 21.9 mEq/L (mmol/L) and correlated inversely with nPCR, serum albumin, and serum phosphorus values. Before and after adjusting for 15 comorbidities, nutrition, and equilibrated Kt/V, a U-curve best represented the association between predialysis serum bicarbonate level and risk for mortality or hospitalization. Patients with midweek predialysis serum bicarbonate levels of 20.1 to 21.0 mEq/L (mmol/L) faced the lowest risk for mortality, whereas those with bicarbonate levels of 21.1 to 22.0 mEq/L faced the lowest risk for hospitalization. Both high (>27 mEq/L) and low (< or =17 mEq/L) serum bicarbonate levels were associated with increased risk for mortality and hospitalization.
CONCLUSION: Moderate predialysis acidosis seems to be associated with better nutritional status and lower relative risk for mortality or hospitalization than is observed in patients with normal ranges of midweek predialysis serum bicarbonate concentration (approximately 24 mEq/L) or severe acidosis (<16 mEq/L).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15384017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  56 in total

Review 1.  Correction of chronic metabolic acidosis for chronic kidney disease patients.

Authors:  P Roderick; N S Willis; S Blakeley; C Jones; C Tomson
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 2.  Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrology (Carlton)       Date:  2009-06       Impact factor: 2.506

3.  Oral bicarbonate: renoprotective in CKD?

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2010-01       Impact factor: 28.314

4.  Case in Point: Correction of Dialysis-Induced Metabolic Alkalosis.

Authors:  Assad Mohammedzein; Tarek Naguib
Journal:  Fed Pract       Date:  2021-04

5.  Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.

Authors:  Markus Ketteler; Marianne Rix; Stanley Fan; Nicholas Pritchard; Ove Oestergaard; Scott Chasan-Taber; Jeremy Heaton; Ajay Duggal; Philip A Kalra
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-01       Impact factor: 8.237

6.  Bicarbonate supplementation slows progression of CKD and improves nutritional status.

Authors:  Ione de Brito-Ashurst; Mira Varagunam; Martin J Raftery; Muhammad M Yaqoob
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

7.  Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial.

Authors:  Andreas Pasch; Geoffrey A Block; Matthias Bachtler; Edward R Smith; Wilhelm Jahnen-Dechent; Spyridon Arampatzis; Glenn M Chertow; Patrick Parfrey; Xiaoye Ma; Juergen Floege
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-09       Impact factor: 8.237

8.  Etiology and outcome of chronic renal failure in hospitalized children in Ho Chi Minh City, Vietnam.

Authors:  Tran Thi Mong Hiep; Françoise Janssen; Khalid Ismaili; Dang Khai Minh; Doan Vuong Kiet; Annie Robert
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

9.  A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.

Authors:  Stanley Fan; Calum Ross; Sandip Mitra; Philip Kalra; Jeremy Heaton; John Hunter; Melissa Plone; Nick Pritchard
Journal:  Nephrol Dial Transplant       Date:  2009-08-07       Impact factor: 5.992

Review 10.  Consequences and therapy of the metabolic acidosis of chronic kidney disease.

Authors:  Jeffrey A Kraut; Nicolaos E Madias
Journal:  Pediatr Nephrol       Date:  2010-06-05       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.